Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005. The Committee for Medical Products for Human Use (CHMP) recommended refusal of marketing authorization on 27 July 2006. The major concern was that efficacy had not been sufficiently shown. In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis.
The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Deferasirox | The serum concentration of Agomelatine can be increased when it is combined with Deferasirox. |
| Peginterferon alfa-2b | The serum concentration of Agomelatine can be increased when it is combined with Peginterferon alfa-2b. |
| Leflunomide | The serum concentration of Agomelatine can be decreased when it is combined with Leflunomide. |
| Teriflunomide | The serum concentration of Agomelatine can be decreased when it is combined with Teriflunomide. |
| Buprenorphine | Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine. |
| Dronabinol | The serum concentration of Dronabinol can be increased when it is combined with Agomelatine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Agomelatine. |
| Hydrocodone | Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine. |
| Magnesium sulfate | The therapeutic efficacy of Agomelatine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Agomelatine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Agomelatine. |
| Mirtazapine | Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Agomelatine. |
| Orphenadrine | Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Agomelatine. |
| Pramipexole | Agomelatine may increase the sedative activities of Pramipexole. |
| Ropinirole | Agomelatine may increase the sedative activities of Ropinirole. |
| Rotigotine | Agomelatine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Agomelatine. |
| Sodium oxybate | Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Agomelatine. |
| Thalidomide | Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Agomelatine. |
| Phenindione | The risk or severity of adverse effects can be increased when Agomelatine is combined with Phenindione. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Agomelatine is combined with 4-hydroxycoumarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Agomelatine is combined with Ethyl biscoumacetate. |
| Clorindione | The risk or severity of adverse effects can be increased when Agomelatine is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Agomelatine is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Agomelatine is combined with Tioclomarol. |
| Caffeine | The serum concentration of Agomelatine can be increased when it is combined with Caffeine. |
| Moxifloxacin | The serum concentration of Agomelatine can be increased when it is combined with Moxifloxacin. |
| Lidocaine | The serum concentration of Agomelatine can be increased when it is combined with Lidocaine. |
| Mexiletine | The serum concentration of Agomelatine can be increased when it is combined with Mexiletine. |
| Imipramine | The serum concentration of Agomelatine can be increased when it is combined with Imipramine. |
| Alosetron | The serum concentration of Agomelatine can be increased when it is combined with Alosetron. |
| Ketoconazole | The serum concentration of Agomelatine can be increased when it is combined with Ketoconazole. |
| Gatifloxacin | The serum concentration of Agomelatine can be increased when it is combined with Gatifloxacin. |
| Simeprevir | The serum concentration of Agomelatine can be increased when it is combined with Simeprevir. |
| Dosulepin | The risk or severity of CNS depression can be increased when Agomelatine is combined with Dosulepin. |
| Lobeglitazone | The serum concentration of Agomelatine can be increased when it is combined with Lobeglitazone. |
| Pazufloxacin | The serum concentration of Agomelatine can be increased when it is combined with Pazufloxacin. |
| Osilodrostat | The serum concentration of Agomelatine can be increased when it is combined with Osilodrostat. |
| Cyproterone acetate | The metabolism of Agomelatine can be increased when combined with Cyproterone acetate. |
| Ethanol | Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine. |
| Citalopram | The risk or severity of adverse effects can be increased when Agomelatine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Agomelatine is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Agomelatine is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Agomelatine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Agomelatine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Agomelatine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Agomelatine is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Agomelatine is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Agomelatine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Agomelatine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Agomelatine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Agomelatine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Agomelatine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Agomelatine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Agomelatine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Agomelatine is combined with Alaproclate. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Nortriptyline is combined with Agomelatine. |
| Desipramine | The risk or severity of CNS depression can be increased when Desipramine is combined with Agomelatine. |
| Carbamazepine | The metabolism of Agomelatine can be increased when combined with Carbamazepine. |
| Primidone | The metabolism of Agomelatine can be increased when combined with Primidone. |
| Rifampin | The metabolism of Agomelatine can be increased when combined with Rifampicin. |
| Albendazole | The metabolism of Agomelatine can be increased when combined with Albendazole. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Agomelatine. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Agomelatine. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Agomelatine. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Agomelatine. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with Agomelatine. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Agomelatine. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Agomelatine. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with Agomelatine. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Agomelatine. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Agomelatine. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Agomelatine. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Agomelatine. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Agomelatine. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Agomelatine. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Agomelatine. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Agomelatine. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with Agomelatine. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Agomelatine. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Agomelatine. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Agomelatine. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Agomelatine. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Agomelatine. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Agomelatine. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Agomelatine. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Agomelatine. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with Agomelatine. |